Prana Biotechnology Operating Income 2010-2021 | ATHE

Prana Biotechnology operating income from 2010 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Prana Biotechnology Annual Operating Income
(Millions of US $)
2021 $-11
2020 $-9
2019 $-9
2018 $-6
2017 $-5
2016 $-6
2015 $-9
2014 $-17
2013 $-13
2012 $-8
2011 $-6
2010 $-4
2009 $-6
Prana Biotechnology Quarterly Operating Income
(Millions of US $)
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.015B $0.003B
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00